Share ownership MBX Biosciences, Inc.

MBX

US55287L1017

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:12:21 2026-04-21 pm EDT			5-day change	1st Jan Change
32.22 ^USD	-4.62%		-0.85%	+3.14%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Share class: MBX Biosciences, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	33,417,418	32,333,580 ( 96.76 %)	0	96.76 %

Major shareholders: MBX Biosciences, Inc.

Name	Equities	%	Valuation
Frazier Life Sciences Management LP 14 %	6,652,013	14 %	199 M $
OrbiMed Advisors Private Equity 7.657 %	3,637,887	7.657 %	109 M $
NEA Management Co. LLC 7.608 %	3,614,486	7.608 %	108 M $
Wellington Trust Co., NA 7.051 %	3,349,961	7.051 %	100 M $
Deep Track Capital LP 6.84 %	3,249,790	6.84 %	97 M $
BlackRock Advisors LLC 5.68 %	2,698,690	5.68 %	81 M $
Norwest Venture Partners 4.497 %	2,136,335	4.497 %	64 M $
EcoR1 Capital, LLC 4.47 %	2,123,604	4.47 %	63 M $
Vanguard Fiduciary Trust Co. 3.826 %	1,817,811	3.826 %	54 M $
Driehaus Capital Management LLC 2.964 %	1,408,159	2.964 %	42 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	96.06%
Other	5.23%
Individuals	2.93%
State Street Corp.	1.42%
Manulife Financial Corp.	0.15%
SEI Investments Co.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	98.8%
Individuals	2.93%
United Kingdom	2.65%
Switzerland	0.59%
Canada	0.4%
Ireland	0.23%
Australia	0.09%
France	0.05%
Cayman Islands	0.04%
China	0.03%

Based on 1000 largest holdings

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Employees

Sector

Biotechnology & Medical Research

More about the company